NYU/Neurocrit.Care: Brain Injury Expert Says Important Changes Still Needed to Law Defining Death Despite Reform Pause

After surveying the views expressed by 41 advocacy, medical, and transplant-focused organizations on the Uniform Determination of Death Act, a brain injury expert is calling for much-needed reforms to the legal definition of death in the United States. The recently announced pause by the Uniform Law Commission, which is spearheading revisions, is disappointing, the expert notes, but should not permanently stall practical fixes to longstanding problems with the Death Act.

“This study shows that most medical organizations support revisions of the Uniform Determination of Death Act to align the legal description of the neurological criteria for death with medical standards,” said Ariane Lewis, MD, a neurocritical care specialist and professor in the Departments of Neurology and Neurosurgery at NYU Grossman School of Medicine.

Specifically, Lewis argues, the legal description for death needs to reflect medical guidelines, which do not require that loss of hormone function be considered when declaring someone brain dead. Moreover, Lewis says, the Death Act needs to be revised to include legal guidance for health care providers about what to do when a family objects to stopping mechanically assisted breathing for a relative who is already brain dead. The act, for example, needs to clarify when and for how long, if not indefinitely, a person can be kept on a ventilator after brain death if a family objects to it being removed.

Lewis says her survey results showed that 34 organizations (83%) favored revisions to the Death Act. However, she acknowledges that views about how to revise it varied. Some religious organizations and patient advocacy groups were opposed to using loss of brain function as a criteria for declaring death, favoring instead the traditional definition of death as having occurred after the heart stops beating.

Lewis, who also serves as director of neurocritical care at NYU Langone Health, has already shared her survey results and perspective with the commission, whose work to amend the Death Act was suspended in late September. Lewis has been one of 100 observers working with the commission for the past three years on revisions to the statute.

Publishing in the journal Neurocritical Care online Oct. 25, the study involved a detailed review of the comments and viewpoints submitted to the commission between January and July 2023 by 41 organizations impacted by the Death Act.

Historically, a person was considered dead when their heart stopped beating and they could no longer breathe on their own. Technological advances in mechanical ventilation changed that, allowing people, in some cases, to keep breathing after they had suffered catastrophic brain injuries leading to coma, and had lost the nerve function needed for them to breathe on their own. Such cases led in 1981 to the U.S. Uniform Determination of Death Act, which defined death as either the irreversible cessation of all brain or cardiopulmonary functions. This definition was adopted by all American states as the legal basis for declaring a person dead.

The act, however, failed to specify the medical tests needed to determine if someone was dead. Furthermore, a small number of states allow families to voice objections on religious grounds. This includes some Orthodox Jews, Muslims, and Catholics who equate withdrawal of mechanical ventilation to euthanasia, even after a person has been declared brain dead. Dozens of lawsuits have been filed against healthcare facilities by families wishing to keep a relative, who has already been declared brain dead, on mechanical ventilation indefinitely.

Citing the need for more legal guidance for physicians, Lewis is calling on the commission to accept international and national medical standards for death by neurological criteria. Among these are guidelines published by the American Academy of Neurology, Society of Critical Care Medicine, American Academy of Pediatrics, and Child Neurology Society, none of which require the loss of hormone function when declaring someone brain dead.

Lewis points out the loss of “all functions of the entire brain,” which could also cover cessation of hormone secretion, is included in the act’s definition of death. However, such loss of hormone function is not needed to be declared dead by brain criteria using current medical standards.

The Death Act’s definition, Lewis argues, is not only too broad, but it is also impractical because there is currently no medically established standard for measuring whether and when hormone secretion from the brain has stopped. Thus, she says, the act should be clarified to specify what brain functions must be lost in order to declare someone legally dead, recognizing that loss of hormone secretion should not be among the criteria.

Another study finding was that patient advocacy groups favored revisions to the act that require family consent before discontinuing mechanical ventilation after a person is declared dead. Medical organizations, Lewis says, are opposed to this position.

“The results of this survey show that while stakeholders support revisions to the Death Act, medical organizations and patient advocacy groups are deeply divided on the approach to do this,” said Lewis. With prospects for consensus slim and the commission’s efforts paused as a result, Lewis concludes that “without revisions to the law, it remains unclear what tests are required for declaring someone brain dead, and physicians and the public do not have legal guidance about how to resolve conflicts when families object to death by brain criteria.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”